Rheumnow Podcast

Join Amanda Mixon, PA-C, for a practical look at the role of the rheumatology advanced practice provider (APP) in recognizing and managing interstitial lung disease (ILD). Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.

The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. dermatology drugs, biologics, andJAK inhibitors - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: Latest #s: EHR estimates from 6 large US medical systems, estimated prevalence of autoimmune Dz (AID) to be 15 million (4.6% US population); 34% have 2+ AID. Women have 2x risk. Sex ratio of 1.7:1 F:M. https://buff.ly/fYgRfZ0 POETYK PsA-1: Deucravacitinib in Biologic-Naïve PsA POETYK PsA-1 trial tested the disease modifying efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in PsA patients and was shown to be superior vs to placebo for clinical responses, patient-reported outcomes, https://t.co/VjwpCVKPz0 MoonLake announced positive phase 3 data from its IZAR-1 RCT using its dual A/F IL-17 inhibitor sonelokimab, showing significant responses at week 16: 66% ACR20, 42% ACR50, 41% minimal disease activity (MDA), & 61% PASI90 at week 16. a 2nd IZAR-2 PsA RCT is in progress https://t.co/eX0cxekRKG British Dermatology Biologics registry (BADBIR) 18976 #PSO pts had incidence serious infxns (SIE) 28 SEI/1000 Pt-Yrs; higher if they had prior infxn (79/1000 PYs). SIE signif lower w/ RIZankizumab (HR 0.74-.80) vs BROAD, ETN, other standards Rxs. SIE deaths rare (1.81/1000 PYs) https://t.co/GTr3DLCVXs 39 studies compared Juvenile systemic sclerosis (jSSc) & adult SSc. 935 jSSc vs 15,451 aSSc pts; jSSc had more diffuse cutaneous dz (70% vs 41%), more overlap myositis (33% vs. 5%), arthritis (33% vs 18%), digital ulcers (51% vs 20%), less renal crisis (0% vs 6%) & lower mortality jSSc (7.7% vs. 20.4%) https://t.co/vflarmwSyv Italian SPRING cohort of #SSc pts found only 5.3% (of 1689 pts) without the typical scleroderma pattern on nailfold change by NVC. They had milder dz, with less vascular dz (pitting scars 33 vs 48%), telangiectasias (52 vs 74%), calcinosis 3.4 vs 12%) & higher DLCOs at 12, 24, https://t.co/AoNAhVYfII Review of CAR-T 29 trials in systemic sclerosis (SSc): 27/29 target CD19 (other CD20, BCMA), 20/29 autologous. Only 2 RCTs; 1 w/ RTX comparator. Most included CREST. Schetts largest series had 6 dcSSc w/ skin/lung improvements. Need fewer & larger multicenter RCTs https://t.co/Me28HbaFhR SLE & Dermatomyositis rashes maybe classically red or violaceous in Whites,but different in people of color, where erythema often appears brown/violaceous, Gottron papules can be mistaken for "dry skin." This delays dx, especially in anti-MDA5+ RP-ILD, where rash may be the https://t.co/Savx5IOTcG Yesterday the EMA approved upadacitinib (Rinvoq) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo - the 1st therapy approved for the most common form of vitiligo. Based on positive results from the Phase 3 Viti-Up trials https://t.co/MMv5LjZclQ 3 Rx are FDA approved for hidradenitis supprativa (secukinumab, adalimumab, bimekizumab). New JAK1i Povorcitinib in STOP-HS1 and STOP-HS2 ph 3 PCTs (608/619 pts). Povo showed HiSCR50 ~42% vs PBO 29% @wk12. AE: acne, pharyngitis https://t.co/n3FJUOjNuo

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com

Listen to Dr. Catherine Bakewell's review of clinical data from a recent label update. Sponsored by Johnson & Johnson Medical Affairs

Dr. Cush reviews the news and journal articles from this past week on RheumNow.com; talking about lumbar belts, scholarships and misdiagnosis.

Dr. Jack Cush reviews the news and journal articles this week where RheumNow featured info on cancer, deadly viruses, AI rules, poetry and good moons rising.

Dr. Jack Cush reviews the news and recent journal reports on RheumNow.com

Dr. Christina Charles-Schoeman and Dr. Manish Jain are back to discuss treatment considerations after TNFi failure in RA. Join them as they review the latest data from SELECT-SWITCH, including post hoc results in primary and secondary nonresponders presented at EULAR 2026. Learn how those findings impact their clinical decision-making. Sponsored by AbbVie Medical Affairs + Health Impact

Dr. Jack Cush Obesity & Gout Dr. Tony Merriman Genome-Wide Association Studies in Gout Dr. Lisa Stamp Gout Management in Patients with Chronic Kidney Disease Dr. Mark Fisher Gout & Mortality  

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com

Dr. Sheila Reyes: QD Clinic: The Highs and Lows of a Woman with Gout   Dr. Jack Cush QD319 A Watched Tophus Never Resolves  Dr. Eric Dein QD316: Addressing Severe Gout Flares  Dr. Janet Pope QD Clinic: RA Mimics — Two Cases That Turned Out to Be Gout 

The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. dermatology drugs, biologics, andJAK inhibitors - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: - 20 yr. Tx trends in 6583 #SSc pts. 2005 to 2025 endothelin receptor antagonists & prostanoids/prostacyclins from 3% to 28%. CCB & PDE-5 inh stable. CTX shifted to mycophenolate, RTX, & nintedanib. Steriods decr from 50% to 18% https://t.co/nrm1Ov285f https://t.co/ftLn3bGH72 Systemic sclerosis metanalysis of 31 studies (32,134 pts) shows malignancy risk signif increased (SIR 1.66; CI 1.32 - 2.08). Highest: esophageal, liver, cervical, lung, & Heme (SIR 3.35 - 13.95). 7.4 yr mean from SSc to CA dx. https://t.co/IhxvfkMqkf RZV (Shingrix) response in 76 immunosuppressed SSc & 304 controls (CG) recv two RZV doses. High seroconversion seen in SSc but signif lower than CG (92.6% vs 99.7%, P 0.001), w/ lower concentration but comparable CMI, lower AE (74% vs 86%) https://t.co/ALlnVEZIAt https://t.co/kYYy2JIo2J Raynauds: Using the Clinical Practice Research Datalink Aurum (PCP) database (1998 - 2023) the prevalence of Raynaud's 894/100 000, or 158449 cases in 2023. More in elderly & females, less in blacks. Incidence rate 46/100K https://buff.ly/TLjMy21 Guidelines to Spot Cancer in High Risk Dermatomyositis Psoriatic Arthritis: EULAR 2026

New, Advanced Therapies in Gout explores the rapidly evolving therapeutic landscape beyond conventional urate-lowering therapy. Join our expert panel as they discuss emerging approaches—including cytokine inhibition, uricase therapies, NLRP3 and URAT-1 inhibitors, and the potential role of GLP-1 receptor agonists and SGLT2 inhibitors—while addressing which patients are most likely to benefit, how these agents fit into current treatment algorithms, and whether novel mechanisms of action have the potential to transform gout management. Panelists: Dr. Herbert Baraf Dr. Ken Saag Dr. Naomi Schlesinger Dr. Jack Cush (moderator)

Dr. Robert Terkeltaub 3 New Things it Pays to Know About Gout Pathobiology Dr. Nicola Dalbeth Outcomes of Tophaceous Gout  Dr. Ted Mikuls Subclinical Inflammation in Intercritical Gout Dr. Michael Pillinger Gout and Cardiovascular Disease: What's the Risk? What's the Connection?

Dr. John Fitzgerald Gout & Metabolic syndrome Dr. Karon Jatuworpruk Predicting and managing gout flares in hospitalised patients Dr. Richard Conway Bespoke Telehealth in Gout: A Missed Opportunity

Dr. Robert Terkeltaub Four things you need to know about allopurinol hypersensitivity syndrome  Dr. Angelo Gaffo Challenges in Gout Diagnosis Dr. Janet Pope Tips for safe use of allopurinol in patients with gout

Dr Janet Pope: QD Clinic: Can RA and Gout Manifest Simultaneously?  Dr. Mrinalini Dey QD312: Gout, Sepsis… or Both?  Daric Mueller, PA-C QD315: Pegloticase Immunomodulation: What's on the Menu?  Dr. Richard Conway: QD313: Don't Presume on IL-1 in Gout 

Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com

Upgrading & Maximizing the Classics (Colchicine, Allopurinol, etc.) examines how to optimize the use of time-tested gout therapies in today's increasingly complex patients. Through practical case discussions, our expert faculty will address colchicine safety and dosing in chronic kidney disease, selecting first-line therapy for acute flares, initiating and titrating urate-lowering therapy, improving treatment adherence, and navigating challenging scenarios such as gout management in patients with CKD and cardiovascular disease. Panelist: Dr. Angelo Gaffo  Dr. Lisa Stamp  Dr. Michael Pillinger  Dr. Ted Mikuls  Moderator: Dr. Jack Cush

Dr. Jack Cush reviews the news, journal articles and Gout features from this past week on RheumNow.com

This webinar explores the evolving role of imaging in the diagnosis and management of gout. Our expert panel will discuss when and how to use ultrasound, dual-energy CT (DECT), crystal identification, and conventional radiography, while addressing practical questions such as the role of imaging in diagnostic uncertainty, serial disease monitoring, and whether ultrasound is changing the need for synovial fluid analysis in everyday practice. Panelists: Dr. Nicola Dalbeth Dr. John Fitzgerald Dr. Sarah Tedeschi Dr. Jack Cush (moderator)

QD307: Senior Year Gout   https://youtu.be/_TGgcdQsfic QD308: Allopurinol for All Gout? Not Quite  https://youtu.be/JAwUb-hqeFs QD309: Cellulitis Paradoxes  https://youtu.be/j3feySk5wQo QD310: Gout: Is it the Journey or the Destination? https://youtu.be/1J-ZrbaGsD8 QD311: When There's Doubt in Gout  https://youtu.be/DpAevfq7Oo0

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month. Visit https://rheumnow.com/campaign/gout-campaign-july-2026 for all of our coverage throughout July.

Gout Journal Club will examine two influential publications: 1. "Treat-to-Target Urate-Lowering Treatment and Cardiovascular Outcomes in Patients with Gout" (Cipolletta et al., JAMA Internal Medicine, 2026) and 2. "Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease"(Wang et al., JAMA Internal Medicine, 2025). Together, these studies provide new evidence supporting treat-to-target urate-lowering strategies and their potential impact on cardiovascular and renal outcomes. Panelists: Abhishek Abhishek, MD, PhD, MBBS, FRCP Zeqin Wen, MD Jie Wei, PhD Jack Cush, MD (moderator) Beyond reviewing the evidence, our expert panel will tackle the practical questions rheumatologists face every day.

In August, Dr. Christina Charles-Schoeman and Dr. Manish Jain will return with a new episode exploring the latest clinical data on RA treatment after TNFi failure. Before that episode drops, revisit their 2025 conversation on disease control, real-world data, and guidelines that inform clinical decision-making after TNFi failure. Sponsored by AbbVie Medical Affairs + Health Impact.

Dr. Jack Cush lectures on giving a great presentation; based on 40 years of lecturing in Rheumatology.

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: - Breckenridge Pharmaceutical received FDA approval for their generic version of tofacitinib on 6/4/26. 5 mg and 10 mg tablets are now available in the U.S. market, for both adult and pediatric use. Tofacitinib Tablets are manufactured in Martorelles, Spain. https://t.co/oAh0KQSFgs - TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/NFIap7DSOr   - BE BOLD: Bimekizumab Beats Risankizumab (LB0001) –H2H trial bimekizumab vs risankizumab in PsA for 24 weeks. At week 16; BKZ better than RZB,  p=0.0058). This advantage was maintained out to week 24 (55% vs 44%; p 0.0001). - RA-BRIDGE and RA-BRANCH: FDA mandated study of the risk of venous thromboembolic events (VTE) taking baricitinib (BARI) or TNF inhibitors. The incidence rate was 0.79/100 PY for BARI combined versus 0.51/100 PY for TNFi. The hazard ratio was 1.606 (95% CI 0.969–2.660), with the upper CI exceeding the pre-specified NI margin of 1.8.  Baricitinib (neither dose) was associated with a higher risk of MACE (HR 1.06), all-cause mortality (HR 0.97), arterial thromboembolism (HR 1.27), or opportunistic infections (HR 1.25).   - Probiotics in Psoriatic Arthritis. (POS0290)    66 PsA patients randomized to receive either placebo or probiotic containing lactobacillus and bifidobacterium strains for 12 weeks.  This trial proves no significant effect with oral probiotic supplementation in PsA.  - CLE and smoking. Smoking reduces efficacy of antimalarials & worsens dz activity & damage. Advocate for smoking cessation! @Rheumnow #EULAR2026 https://t.co/pEWLJAkBAJ - Risk of Psoriasis is increased 19% by long-term exposure to Particulate Matter (PM2.5 & PM10; adjHR 1.19), while short-term exposure increases risk of psoriasis exacerbation (adjusted OR 1.03). Stronger in younger, urban, lower SES, ever-smokers, & comorbid allergies https://t.co/pd6S13RG1B

Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.

Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology's most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the EULAR 2026 meeting in London.

Join Drs. Bella Mehta, Jack Cush, Janet Pope, and Jon Kay for a focused conversation on the latest in rheumatoid arthritis care from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping RA practice right now.

Join Drs. Jack Cush, Alfred Kim, Janet Pope, and Yuz Yusof for a focused conversation on the latest in CAR-T from emerging data and treatment strategies to real-world challenges in diagnosis and management. Hear expert perspectives, clinical pearls, and what's shaping CAR-T practice right now.

Join Drs. Jack Cush, Peter Nash, Antoni Chan, and Nelly Ziade for an expert discussion on the most important psoriatic arthritis developments emerging from EULAR 2026. This focused conversation explores new clinical data, evolving treatment strategies, and practical approaches to managing PsA in everyday practice. From advances in biologic and targeted therapies to ongoing challenges in diagnosis, disease monitoring, and patient care, the panel shares key insights and take-home messages that every rheumatology clinician should know. Tune in for expert perspectives, clinical pearls, and a comprehensive look at what's shaping the future of psoriatic arthritis management.

2026 EULAR Preview Beyond BMI: Altered Body Composition in Rheumatoid Arthritis CAR-T For Rheumatoid Arthritis This Is a Woman's World: Women's Health in Rheumatic Disease Low dose Blinatumomab: Many Relapse with an Unexpected Surprise Doctor's Orders or Patient's Choice: BACH study findings Another Way to Leverage NK Cells to Kill B Cells, This Time Without CARs Digital Patient Education in RA Making Methotrexate More Effective Are we failing in the treatment of RA-ILD? Using AI to Predict Progression to RA Treat to Target Works in Elderly Onset RA RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk Improving Referrals for Inflammatory Arthritis Combination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease

2026 EULAR Preview Imaging in Subclinical Psoriatic Arthritis Dietary Interventions in PsA This Is a Woman's World: Women's Health in Rheumatic Disease Impact of Synovial Biopsy-Driven Therapeutic Stratification in PsA Can We Stop PsA Before it Starts? BE BOLD: Going Where No PsA Trial Has Gone Before BMI Outranks Treatment in PsA Outcomes? Debate: Combination Therapies for Inflammatory Arthritis? Combination Biologics in PsA: MRI Findings from AFFINITY Combination Therapy in SpA The Case for Dual Pathway Blockade in Refractory PsA The AFFINITY Study: Combination Treatment in PsA PsA Potpourri: Probiotics & Head-to-Head Data Transition from Psoriasis to Psoriatic Arthritis MACE and Safety Profile of bDMARDs/JAKis in axSpA and PsA Guselkumab Delivers Across the PsA Disease Spectrum: APEX Trial  

2026 EULAR Preview CAR-T For Rheumatoid Arthritis What Happens when CAR-T Fails Managing Disease Recurrence Management of Relapses After CAR-T Therapy in SLE, SSc and IIM How Many CAR-Ts Do We Need to Test Drive?

Guselkumab Delivers Across the PsA Disease Spectrum: APEX Trial RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk Improving Referrals for Inflammatory Arthritis" Combination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease

Are we failing in the treatment of RA-ILD? Using AI to Predict Progression to RA Treat to Target Works in Elderly Onset RA

MACE and Safety Profile of bDMARDs/JAKis in axSpA and PsA How Many CAR-Ts Do We Need to Test Drive? Making Methotrexate More Effective

Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Day 4 of the EULAR 2026 Congress. Abstracts discussed included: LB001 LB002 LB003 LB005 LB007 LB009 RA Plenary POS1350

Debate: Combination Therapies for Inflammatory Arthritis? Combination Biologics in PsA: MRI Findings from AFFINITY Combination Therapy in SpA Digital Patient Education in RA The Case for Dual Pathway Blockade in Refractory PsA The AFFINITY Study: Combination Treatment in PsA PsA Potpourri: Probiotics & Head-to-Head Data Transition from Psoriasis to Psoriatic Arthritis  

Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Days 3 of the EULAR 2026 Congress. Abstracts discussed included: OP0348  POS0290  OP0342  POS1068  POS0201  POS0288

BE BOLD: Going Where No PsA Trial Has Gone Before BMI Outranks Treatment in PsA Outcomes? What Happens when CAR-T Fails Managing Disease Recurrence Management of Relapses After CAR-T Therapy in SLE, SSc and IIM Doctor's Orders or Patient's Choice: BACH study findings Another Way to Leverage NK Cells to Kill B Cells, This Time Without CARs

Low dose Blinatumomab: Many Relapse with an Unexpected Surprise Can We Stop PsA Before it Starts? Impact of Synovial Biopsy-Driven Therapeutic Stratification in PsA

Join Dr. Jack Cush and RheumNow.com faculty for a lively discussion of the top presentations, breakthrough science, and clinical pearls from Days 1 & 2 of the EULAR 2026 Congress. Abstracts discussed included: OP0177 OP0244   OP001 OP008 OP0205  OP018 OP0204 POS0788

Imaging in Subclinical Psoriatic Arthritis CAR-T For Rheumatoid Arthritis This Is a Woman's World: Women's Health in Rheumatic Disease Dietary Interventions in PsA

2026 EULAR Preview - Dr. Jack Cush ‘Strong' Treatment Predictions in Inflammatory Myositis - Dr. Janet Pope Beyond BMI: Altered Body Composition in Rheumatoid Arthritis - Dr Mrinalini Dey Why PROMS Matter in the Care of People with Lupus - Dr. Mrinalini Dey

Dr. Jack Cush reviews the news, journal articles and missed quiz question.

Dr. Jack Cush talks of birthdays, Quizes and journal articles this week on the podcast.

Dr. Jack Cush discusses his favorite journal articles from the past week on RheumNow.com.

Dr Jack Cush reviews the news and journal reports from last weekon rheumnow.com